MindBio Therapeutics Corp.
MBIO
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -200.48% | -201.55% | -- |
| Total Revenue | -- | -- | -200.48% | -201.55% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -200.48% | -201.55% | -- |
| SG&A Expenses | 463.56% | 212.46% | -87.68% | -84.16% | -83.74% |
| Depreciation & Amortization | 400.00% | 350.00% | -106.06% | 6,575.00% | 97.50% |
| Other Operating Expenses | -3.93% | -44.20% | -44.20% | -44.20% | -44.20% |
| Total Operating Expenses | 441.69% | 193.39% | -87.13% | -82.39% | -83.05% |
| Operating Income | -438.71% | -191.98% | 60.80% | 74.93% | 82.96% |
| Income Before Tax | -1,339.62% | -563.20% | 55.98% | 84.73% | 93.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1,339.62% | -563.20% | 55.98% | 84.73% | 93.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 100.00% | -150.00% | 1,500.00% | 1,100.00% | -300.00% |
| Net Income | -1,336.26% | -563.65% | 56.12% | 84.82% | 93.76% |
| EBIT | -438.71% | -191.98% | 60.80% | 74.93% | 82.96% |
| EBITDA | -1,092.19% | -687.62% | -186.49% | 145.55% | 204.79% |
| EPS Basic | -361.55% | -175.36% | -16.37% | 73.73% | 90.35% |
| Normalized Basic EPS | -236.61% | -83.56% | 26.03% | 72.54% | 90.08% |
| EPS Diluted | -361.55% | -175.36% | -16.37% | 73.73% | 90.35% |
| Normalized Diluted EPS | -236.61% | -83.56% | 26.03% | 72.54% | 90.08% |
| Average Basic Shares Outstanding | 144.71% | 89.31% | -33.88% | -22.93% | -18.61% |
| Average Diluted Shares Outstanding | 144.71% | 89.31% | -33.88% | -22.93% | -18.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |